The biotech stock with the BofA's biggest upside already has approval for a drug that treats a rare kidney disease affecting up to 150,000 people in the U.S.
from International: Top News And Analysis https://ift.tt/6G0aOpl
via IFTTT
Monday, December 18, 2023
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment